Related Experiment Videos
Factor V Leiden in central venous catheter-associated thrombosis
Rob Fijnheer1, Birgit Paijmans, Leo F Verdonck
1Department of Haematology, University Medical Center Utrecht (UMCU), Utrecht, The Netherlands. R.Fijnheer@azu.nl
British Journal of Haematology
|July 9, 2002
Summary
Factor V Leiden mutation significantly increases subclavian vein thrombosis risk in bone marrow transplant patients with central venous catheters. Testing and prophylaxis are recommended for these high-risk individuals.
Area of Science:
- Vascular Medicine
- Hematology
- Transplantation
Background:
- Subclavian vein thrombosis is a known complication of central venous catheter insertion.
- Factor V Leiden mutation is a risk factor for venous thromboembolism.
Purpose of the Study:
- To investigate the association between factor V Leiden mutation and central venous catheter-associated subclavian vein thrombosis in bone marrow transplant recipients.
Main Methods:
- Prospective study of 277 bone marrow transplant patients with subclavian central venous catheters.
- Diagnosis of thrombosis via clinical signs and confirmed by color-flow Doppler ultrasound.
- Factor V Leiden mutation status determined for all patients.
Main Results:
- Patients with factor V Leiden mutation had a 54% rate of subclavian vein thrombosis versus 9% in negative patients (Relative Risk 7.7).
- Factor V Leiden accounted for 17.3% of all catheter-associated thrombosis.
- The majority of factor V Leiden-positive patients developed thrombosis.
Conclusions:
- Factor V Leiden mutation is a significant risk factor for subclavian vein thrombosis in patients with central venous catheters.
- Recommend thrombosis prophylaxis and prompt catheter removal for factor V Leiden-positive patients.
- Advise factor V Leiden screening for all bone marrow transplant patients receiving central venous catheters.